Transdermal Drug Delivery Systems Market Report by Technology, Application, and Region 2024-2032
세계 경피 약물전달 시스템 시장 규모는 2023년 67억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장 규모가 111억 달러에 달하고 2024-2032년 연평균 성장률(CAGR)이 5.5%에 달할 것으로 예측했습니다.
경피 약물전달 시스템(TDDS)은 약물을 피부에서 전신으로 전달하는 대체 시스템입니다. 경피 약물전달 시스템(TDDS)은 경구용 혈관 내, 피하, 경점막 경로의 대안으로 사용되며, 약물이나 화장품과 같은 생물학적 활성 약물을 피부를 통해 전달하기 때문에 만성질환, 급성질환, 미용시술을 모두 지원하며, 약물의 방출을 조절할 수 있어 초기 통과 대사의 영향을 줄이고, 부작용을 줄이고, 치료 기간 동안 안정적인 혈중 약물 프로파일을 가능하게 하여 투여 효과를 향상시킵니다.
경피 약물전달 시스템 시장 동향
세계 경피 약물전달 시스템 시장은 경구용 의약품과 같은 기존 약물전달 시스템으로 치료할 수 없는 만성 질환의 사례가 증가하고 있는 것이 주요 요인으로 작용하고 있습니다. 당뇨병과 같은 장기적인 질환을 앓고 있는 환자들은 자가 투약으로 전환하고 있습니다. 그 결과, 통증 없이 매일 약을 복용할 수 있는 점착성 피부 패치가 등장했습니다. 이 때문에 환자와 의사들은 통증 없는 약물전달 시스템을 선호하고 있습니다. 여기에 더해 이온영동과 같은 3세대 경피 약물전달 시스템이 널리 채택되면서 잦은 병원 방문이 줄어들고 누적된 치료 비용도 줄어들어 환자의 자립을 촉진하고 있습니다. 또한, 마이크로 니들, 경피 패치 디자인 변경, 압력에 민감한 접착제 및 침투 촉진제의 통합과 같은 기술 발전은 제조업체에 큰 기회를 제공하고 있습니다.
본 보고서에서 다루는 주요 질문들
- 세계 경피 약물전달 시스템 시장은 지금까지 어떻게 성장해 왔을까?
- COVID-19는 전 세계 경피 약물전달 시스템 시장에 어떤 영향을 미치고 있는가?
- 주요 지역 시장이란?
- 기술별 시장 현황은?
- 용도별 시장 내역은?
- 산업 가치사슬의 다양한 단계는 무엇인가?
- 업계의 주요 촉진요인과 과제는 무엇인가?
- 세계 경피 약물전달 시스템 시장 구조와 주요 진출기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 경피 약물전달 시스템 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 기술별
- 일렉트로포레이션
- 무선주파수
- 이온토포레시스
- 마이크로포레이션
- 서멀
- 기계 어레이
- 초음파
- 기타
제7장 시장 내역 : 용도별
제8장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제12장 가격 분석
제13장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- 3M Company
- Acrux Limited
- Boehringer Ingelheim International GmbH
- Hisamitsu Pharmaceutical Co. Inc.
- Lavipharm S.A.
- LEAD CHEMICAL Co. Ltd.
- Luye Pharma Group
- Nutriband Inc.
- Viatris Inc.
ksm
The global transdermal drug delivery systems market size reached US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.5% during 2024-2032.
The transdermal drug delivery system (TDDS) is an alternative system of delivering drugs through the skin for systemic distribution. It is used as an alternative to oral intravascular, subcutaneous, and transmucosal routes. TDDS supports both chronic and acute diseases as well as cosmetic procedures as it delivers biologically active agents, such as drugs and cosmeceuticals, through the skin. It offers a controlled release of drugs, which reduces the first-pass metabolism effects, lessens the side effects, and improves the efficacy of the dosage by enabling a steady blood drug profile throughout the treatment.
Transdermal Drug Delivery System Market Trends:
The global transdermal drug delivery systems market is primarily driven by the growing instances of chronic disorders that cannot be treated through conventional drug delivery systems, such as oral drugs. Patients with long-term ailments, such as diabetes, are shifting toward self-administration of medicine. As a result, there has been an introduction of adhesive skin patches to administer the daily course of medication without the pain. This has encouraged patients and physicians to prefer pain-free drug delivery systems. Besides this, the wide adoption of third-generation transdermal drug delivery systems like iontophoresis promotes self-reliance in patients since it reduces frequent visits to hospitals and lessens the cumulative treatment costs. Furthermore, technological advancements, such as the inclusion of microneedles, modifications in transdermal patch designs and the incorporation of pressure-sensitive adhesives and permeation enhancers, are providing vast opportunities to manufacturers.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global transdermal drug delivery systems market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on technology and application.
Breakup by Technology:
Electroporation
Radiofrequency
Iontophoresis
Microporation
Thermal
Mechanical Arrays
Ultrasound
Others
Breakup by Application:
Central Nervous System
Pain Management
Cardiovascular
Hormone
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Acrux Limited, Boehringer Ingelheim International GmbH, Hisamitsu Pharmaceutical Co. Inc., Lavipharm S.A., LEAD CHEMICAL Co. Ltd., Luye Pharma Group, Nutriband Inc. and Viatris Inc.
Key Questions Answered in This Report:
- How has the global transdermal drug delivery systems market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global transdermal drug delivery systems market?
- What are the key regional markets?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global transdermal drug delivery systems market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Transdermal Drug Delivery Systems Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Technology
- 6.1 Electroporation
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Radiofrequency
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Iontophoresis
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Microporation
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Thermal
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Mechanical Arrays
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Ultrasound
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
- 6.8 Others
- 6.8.1 Market Trends
- 6.8.2 Market Forecast
7 Market Breakup by Application
- 7.1 Central Nervous System
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Pain Management
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Cardiovascular
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Hormone
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 3M Company
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Acrux Limited
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Boehringer Ingelheim International GmbH
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Hisamitsu Pharmaceutical Co. Inc.
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.5 Lavipharm S.A.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.6 LEAD CHEMICAL Co. Ltd.
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.7 Luye Pharma Group
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.8 Nutriband Inc.
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.9 Viatris Inc.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
